Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial.

ABSTRACT:

Background

RIFAQUIN was a tuberculosis chemotherapy trial in southern Africa including regimens with high-dose rifapentine with moxifloxacin. Here, the application of whole-genome sequencing (WGS) is evaluated within RIFAQUIN for identifying new infections in treated patients as either relapses or reinfections. WGS is further compared with mycobacterial interspersed repetitive units-variable number tandem repeats (MIRU-VNTR) typing. This is the first report of WGS being used to evaluate new infections in a completed clinical trial for which all treatment and epidemiological data are available for analysis.

Methods

DNA from 36 paired samples of Mycobacterium tuberculosis cultured from patients before and after treatment was typed using 24-loci MIRU-VNTR, in silico spoligotypi

SUBMITTER: Witney AA 

PROVIDER: S-EPMC5371199 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature